Arcus Biosciences holder plans sale of 6,552 common shares

Arcus Biosciences Inc. has a notice of proposed sale under Rule 144 for 6,552 shares of common stock, to be sold through Merrill Lynch on the NYSE around 12/31/2025, with an aggregate market value of $153,185.76.

Accepted by SEC EDGAR 12/31/2025 - 06:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Arcus Biosciences Inc. has a notice of proposed sale under Rule 144 for 6,552 shares of common stock, to be sold through Merrill Lynch on the NYSE around 12/31/2025, with an aggregate market value of $153,185.76. Common shares outstanding were 107,973,536.

The seller, Robert C. Goeltz II, acquired these 6,552 shares on 12/15/2025 as a restricted stock unit grant from Arcus Biosciences, recorded as equity compensation. Over the prior three months, he reported multiple sales of common stock: 5,000 shares on 10/28/2025 for $100,000, 5,000 shares on 11/26/2025 for $125,000, 6,702 shares on 12/16/2025 for $146,668.58, and 5,960 shares on 12/17/2025 for $132,070.62.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Arcus Biosciences (RCUS) Form 144 filing disclose?

The filing reports a proposed sale of 6,552 Arcus Biosciences common shares on the NYSE through Merrill Lynch, with an aggregate market value of $153,185.76.

Who is the seller in the Arcus Biosciences (RCUS) Form 144 notice?

The securities are to be sold for the account of Robert C. Goeltz II, whose address is listed as 3928 Point Eden Way, Hayward, CA 94545.

How were the 6,552 Arcus Biosciences shares being sold under Rule 144 acquired?

The 6,552 common shares were acquired on 12/15/2025 as a restricted stock unit award from Arcus Biosciences Inc., categorized as equity compensation.

What prior Arcus Biosciences share sales are reported in the past 3 months?

The seller reported four prior sales of Arcus Biosciences common stock: 5,000 shares on 10/28/2025 for $100,000, 5,000 shares on 11/26/2025 for $125,000, 6,702 shares on 12/16/2025 for $146,668.58, and 5,960 shares on 12/17/2025 for $132,070.62.

How many Arcus Biosciences shares are outstanding in this Form 144 filing?

The notice states that 107,973,536 shares of Arcus Biosciences common stock were outstanding.

On which exchange will the Arcus Biosciences (RCUS) shares be sold according to the notice?

The proposed 6,552-share sale of Arcus Biosciences common stock is listed to occur on the NYSE, with Merrill Lynch as the broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001653881
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcus Biosciences, Inc.
SEC File Number	001-38419
Address of Issuer	3928 Point Eden Way Hayward CALIFORNIA 94545
Phone	510-694-6200
Name of Person for Whose Account the Securities are To Be Sold	Robert C. Goeltz II
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 555 California St Ste 1800 San Francisco CA 94104	6552	153185.76	107973536	12/31/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/15/2025	Restricted Stock Unit	Arcus Biosciences Inc.			6552	12/15/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert C. Goeltz II 3928 POINT EDEN WAY Hayward CA 94545	Common	10/28/2025	5000	100000
Robert C. Goeltz II 3928 POINT EDEN WAY Hayward CA 94545	Common	11/26/2025	5000	125000
Robert C. Goeltz II 3928 POINT EDEN WAY Hayward CA 94545	Common	12/16/2025	6702	146668.58
Robert C. Goeltz II 3928 POINT EDEN WAY Hayward CA 94545	Common	12/17/2025	5960	132070.62

144: Remarks and Signature

Remarks	10b5-1 plan modified on 2/23/2024
Date of Notice	12/31/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/07/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Robert Goeltz
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)